2016 Alzheimer's disease facts and figures
- PMID: 27570871
- DOI: 10.1016/j.jalz.2016.03.001
2016 Alzheimer's disease facts and figures
Abstract
This report describes the public health impact of Alzheimer's disease, including incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers and society. It also examines in detail the financial impact of Alzheimer's on families, including annual costs to families and the difficult decisions families must often make to pay those costs. An estimated 5.4 million Americans have Alzheimer's disease. By mid-century, the number of people living with Alzheimer's disease in the United States is projected to grow to 13.8 million, fueled in large part by the aging baby boom generation. Today, someone in the country develops Alzheimer's disease every 66 seconds. By 2050, one new case of Alzheimer's is expected to develop every 33 seconds, resulting in nearly 1 million new cases per year. In 2013, official death certificates recorded 84,767 deaths from Alzheimer's disease, making it the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age ≥ 65 years. Between 2000 and 2013, deaths resulting from stroke, heart disease, and prostate cancer decreased 23%, 14%, and 11%, respectively, whereas deaths from Alzheimer's disease increased 71%. The actual number of deaths to which Alzheimer's disease contributes is likely much larger than the number of deaths from Alzheimer's disease recorded on death certificates. In 2016, an estimated 700,000 Americans age ≥ 65 years will die with Alzheimer's disease, and many of them will die because of the complications caused by Alzheimer's disease. In 2015, more than 15 million family members and other unpaid caregivers provided an estimated 18.1 billion hours of care to people with Alzheimer's and other dementias, a contribution valued at more than $221 billion. Average per-person Medicare payments for services to beneficiaries age ≥ 65 years with Alzheimer's disease and other dementias are more than two and a half times as great as payments for all beneficiaries without these conditions, and Medicaid payments are 19 times as great. Total payments in 2016 for health care, long-term care and hospice services for people age ≥ 65 years with dementia are estimated to be $236 billion. The costs of Alzheimer's care may place a substantial financial burden on families, who often have to take money out of their retirement savings, cut back on buying food, and reduce their own trips to the doctor. In addition, many family members incorrectly believe that Medicare pays for nursing home care and other types of long-term care. Such findings highlight the need for solutions to prevent dementia-related costs from jeopardizing the health and financial security of the families of people with Alzheimer's and other dementias.
Similar articles
-
2015 Alzheimer's disease facts and figures.Alzheimers Dement. 2015 Mar;11(3):332-84. doi: 10.1016/j.jalz.2015.02.003. Alzheimers Dement. 2015. PMID: 25984581
-
2014 Alzheimer's disease facts and figures.Alzheimers Dement. 2014 Mar;10(2):e47-92. doi: 10.1016/j.jalz.2014.02.001. Alzheimers Dement. 2014. PMID: 24818261
-
2021 Alzheimer's disease facts and figures.Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23. Alzheimers Dement. 2021. PMID: 33756057
-
The costs of Alzheimer's disease and the value of effective therapies.Am J Manag Care. 2011 Nov;17 Suppl 13:S356-62. Am J Manag Care. 2011. PMID: 22214393 Review.
-
Socio-economic Aspects of Alzheimer's Disease.Curr Alzheimer Res. 2015;12(9):903-11. doi: 10.2174/156720501209151019111448. Curr Alzheimer Res. 2015. PMID: 26510983 Review.
Cited by
-
The use of saliva steroids (cortisol and DHEA-s) as biomarkers of changing stress levels in people with dementia and their caregivers: A pilot study.Sci Prog. 2021 Apr-Jun;104(2):368504211019856. doi: 10.1177/00368504211019856. Sci Prog. 2021. PMID: 34030538 Free PMC article.
-
Neuronal cell death mechanisms in Alzheimer's disease: An insight.Front Mol Neurosci. 2022 Aug 25;15:937133. doi: 10.3389/fnmol.2022.937133. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36090249 Free PMC article. Review.
-
Artemisinin Improved Neuronal Functions in Alzheimer's Disease Animal Model 3xtg Mice and Neuronal Cells via Stimulating the ERK/CREB Signaling Pathway.Aging Dis. 2020 Jul 23;11(4):801-819. doi: 10.14336/AD.2019.0813. eCollection 2020 Jul. Aging Dis. 2020. PMID: 32765947 Free PMC article.
-
Building research in diet and cognition (BRIDGE): Baseline characteristics of older obese African American adults in a randomized controlled trial to examine the effect of the Mediterranean diet with and without weight loss on cognitive functioning.Prev Med Rep. 2020 Dec 31;22:101302. doi: 10.1016/j.pmedr.2020.101302. eCollection 2021 Jun. Prev Med Rep. 2020. PMID: 33665063 Free PMC article.
-
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.Int J Mol Sci. 2021 Mar 10;22(6):2805. doi: 10.3390/ijms22062805. Int J Mol Sci. 2021. PMID: 33802091 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical